<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>LIVALO- pitavastatin calciumÂ tablet, film coatedÂ </strong><br>Kowa Pharmaceuticals America, Inc. <br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use LIVALO<span class="Sup">Â®</span> safely and effectively.  See full prescribing information for LIVALO.  <br>LIVALO (pitavastatin) Tablet, Film Coated for Oral use<br>Initial U.S. Approval: 2009
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div><p class="Highlighta">None 
 </p></div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">LIVALO is a HMG-CoA reductase inhibitor indicated for:
 </p>
<ul class="Disc"><li>Patients with primary <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span> or  mixed <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">dyslipidemia</span> as an adjunctive therapy to diet to reduce elevated total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> (TC), low-density lipoprotein <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> (LDL-C), <span class="product-label-link" type="condition" conceptid="4122128" conceptname="Apolipoprotein">apolipoprotein</span> B (<span class="product-label-link" type="condition" conceptid="4098284" conceptname="Apolipoprotein B">Apo B</span>), triglycerides (TG), and to increase high-density lipoprotein <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> (HDL-C) (<a href="#s2">1.1</a>)
</li></ul>
<p class="Highlighta"><span class="Bold">Limitations of Use (<a href="#s3">1.2</a>):</span> </p>
<ul class="Disc">
<li>Doses of LIVALO greater than 4 mg once daily were associated with an increased risk for severe <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> in premarketing clinical studies. Do not exceed 4 mg once daily dosing of LIVALO.
</li>
<li>The effect of LIVALO on cardiovascular morbidity and mortality has not been determined.
</li>
<li>LIVALO has not been studied in Fredrickson Type I, III, and V <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">dyslipidemias</span>.
</li>
</ul>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul class="Disc">
<li>LIVALO can be taken with or without food, at any time of day (<a href="#s5">2.1</a>) Dose Range: 1 mg to 4 mg once daily (<a href="#s5">2.1</a>)
</li>
<li>
<span class="Bold">Primary <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span> and mixed <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">dyslipidemia</span>:</span> Starting dose 2 mg.  When lowering of LDL-C is insufficient, the dosage may be increased to a maximum of 4 mg per day. (<a href="#s5">2.1</a>)
</li>
<li>
<span class="Bold">Moderate and severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (glomerular filtration rate 30 â€“ 59 and 15 - 29  mL/min/1.73 m</span><span class="Bold"><span class="Sup">2</span></span><span class="Bold">, respectively) as well as end-stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> on hemodialysis:</span> Starting dose of 1 mg once daily and maximum dose of 2 mg once daily (<a href="#s6">2.2</a>)
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><ul class="Disc"><li>Tablets: 1 mg, 2 mg, and 4 mg (<a href="#s9">3</a>)
</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul class="Disc">
<li>Known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to product components (<a href="#s10">4</a>)
</li>
<li>Active liver disease, which may include unexplained persistent elevations in hepatic transaminase levels (<a href="#s10">4</a>)
</li>
<li>Women who are pregnant or may become pregnant (<a href="#s10">4</a>, <a href="#s27">8.1</a>)
</li>
<li>Nursing mothers (<a href="#s10">4</a>, <a href="#s29">8.3</a>)
</li>
<li>Co-administration with cyclosporine (<a href="#s10">4</a>, <a href="#s19">7.1</a>, <a href="#s39">12.3</a>)
</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disc">
<li>
<span class="Bold">Skeletal muscle effects (e.g., <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> and <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>):</span> Risks increase in a dose-dependent manner, with advanced age (â‰¥65), <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, and inadequately treated <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span>. Advise patients to promptly report unexplained and/or persistent <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pain</span>, <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>, or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, and discontinue LIVALO (<a href="#s12">5.1</a>)
</li>
<li>
<span class="Bold">Liver enzyme abnormalities:</span> Persistent elevations in hepatic transaminases can occur.  Check liver enzyme tests before initiating therapy and as clinically indicated thereafter  (<a href="#s13">5.2</a>)
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">The most frequent adverse reactions (rate â‰¥2.0% in at least one marketed dose) were <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> and <span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">pain in extremity</span>. (<a href="#s15">6</a>)
 </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Kowa Pharmaceuticals America, Inc. at 1-877-334-3464 or FDA at 1-800-FDA-1088 or
</span><span class="Bold Italics">www.fda.gov/medwatch.</span> </p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul class="Disc">
<li>
<span class="Bold">Erythromycin:</span> Combination increases pitavastatin exposure. Limit LIVALO to 1 mg once daily (<a href="#s7">2.3</a>, <a href="#s20">7.2</a>)
</li>
<li>
<span class="Bold">Rifampin:</span> Combination increases pitavastatin exposure. Limit LIVALO to 2 mg once daily (<a href="#s8">2.4</a>, <a href="#s21">7.3</a>)
</li>
<li>
<span class="Bold">Concomitant lipid-lowering therapies</span>: Use with fibrates or lipid-modifying doses (â‰¥1 g/day) of niacin increases the risk of adverse skeletal muscle effects. Caution should be used when prescribing with LIVALO.  (<a href="#s12">5.1</a>, <a href="#s22">7.4</a>, <a href="#s23">7.5</a>)
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul class="Disc">
<li>
<span class="Bold">Pediatric use:</span> Safety and effectiveness have not been established. (<a href="#s30">8.4</a>)
</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal impairment</span>:</span> Limitation of a starting dose of LIVALO 1 mg once daily and a maximum dose of LIVALO 2 mg once daily for patients with moderate and severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> as well as patients receiving hemodialysis (<a href="#s6">2.2</a>, <a href="#s32">8.6</a>)
</li>
</ul></div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
</div>
<div>
<div></div>
<div><div></div></div>
</div>
<div><div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div></div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 10/2013</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE
</a></h1>
<h2><a href="#section-1.1" class="toc">1.1 Primary <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">Hyperlipidemia</span> and Mixed <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">Dyslipidemia</span>
</a></h2>
<h2><a href="#section-1.2" class="toc">1.2 Limitations of Use
</a></h2>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION
</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 General Dosing Information
</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Dosage in Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>
</a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Use with Erythromycin
</a></h2>
<h2><a href="#section-2.4" class="toc">2.4 Use with Rifampin
</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS
</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS
</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS
</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Skeletal Muscle Effects
</a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Liver Enzyme Abnormalities
</a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Endocrine Function
</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS
</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Studies Experience
</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Postmarketing Experience
</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS
</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Cyclosporine
</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Erythromycin
</a></h2>
<h2><a href="#section-7.3" class="toc">7.3 Rifampin
</a></h2>
<h2><a href="#section-7.4" class="toc">7.4 Gemfibrozil
</a></h2>
<h2><a href="#section-7.5" class="toc">7.5 Other Fibrates
</a></h2>
<h2><a href="#section-7.6" class="toc">7.6 Niacin
</a></h2>
<h2><a href="#section-7.7" class="toc">7.7 Colchicine
</a></h2>
<h2><a href="#section-7.8" class="toc">7.8 Warfarin
</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS
</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy
</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers
</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use
</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use
</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>
</a></h2>
<h2><a href="#section-8.6" class="toc">8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>
</a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE
</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION
</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY
</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action
</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics
</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics
</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY
</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
</a></h2>
<h2><a href="#section-12.2" class="toc">13.2 Animal Toxicology and/or Pharmacology
</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES
</a></h1>
<h2><a href="#section-13.1" class="toc">14.1 Primary <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">Hyperlipidemia</span> or Mixed <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">Dyslipidemia</span>
</a></h2>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING
</a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION
</a></h1>
<h2><a href="#section-15.1" class="toc">17.1 Dosing Time
</a></h2>
<h2><a href="#section-15.2" class="toc">17.2 <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Muscle Pain</span>
</a></h2>
<h2><a href="#section-15.3" class="toc">17.3 Pregnancy
</a></h2>
<h2><a href="#section-15.4" class="toc">17.4 Breastfeeding
</a></h2>
<h2><a href="#section-15.5" class="toc">17.5 Liver Enzymes
</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="dcl-dpl"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="s1"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE
</h1>
<p class="First">Drug therapy should be one component of multiple-risk-factor intervention in individuals who require modifications of their lipid profile. Lipid-altering agents should be used in addition to a diet restricted in saturated fat and <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> only when the response to diet and other nonpharmacological measures has been inadequate.
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s2"></a><a name="section-1.1"></a><p></p>
<h2>1.1 Primary <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">Hyperlipidemia</span> and Mixed <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">Dyslipidemia</span>
</h2>
<p class="First">LIVALO<span class="Sup">Â®</span> is indicated as an adjunctive therapy to diet to reduce elevated total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> (TC), low-density lipoprotein <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> (LDL-C), <span class="product-label-link" type="condition" conceptid="4122128" conceptname="Apolipoprotein">apolipoprotein</span> B (<span class="product-label-link" type="condition" conceptid="4098284" conceptname="Apolipoprotein B">Apo B</span>), triglycerides (TG), and to increase HDL-C in adult patients with primary <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span> or mixed <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">dyslipidemia</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s3"></a><a name="section-1.2"></a><p></p>
<h2>1.2 Limitations of Use
</h2>
<p class="First">Doses of LIVALO greater than 4 mg once daily were associated with an increased risk for severe <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> in premarketing clinical studies. Do not exceed 4 mg once daily dosing of LIVALO.
</p>
<p>The effect of LIVALO on cardiovascular morbidity and mortality has not been determined.
</p>
<p>LIVALO has not been studied in Fredrickson Type I, III, and V <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">dyslipidemias</span>.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s4"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s5"></a><a name="section-2.1"></a><p></p>
<h2>2.1 General Dosing Information
</h2>
<p class="First">The dose range for LIVALO is 1 to 4Â mg orally once daily at any time of the day with or without food. The recommended starting dose is 2Â mg and the maximum dose is 4Â mg. The starting dose and maintenance doses of LIVALO should be individualized according to patient characteristics, such as goal of therapy and response.
</p>
<p>After initiation or upon titration of LIVALO, lipid levels should be analyzed after 4 weeks and the dosage adjusted accordingly.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s6"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Dosage in Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>
</h2>
<p class="First">Patients with moderate and severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (glomerular filtration rate 30 â€“ 59 mL/min/1.73 m<span class="Sup">2</span> and 15 â€“ 29 mL/min/1.73 m<span class="Sup">2</span>   not receiving hemodialysis, respectively) as well as end-stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> receiving hemodialysis should receive a starting dose of   LIVALO 1 mg once daily and a maximum dose of LIVALO 2 mg once daily.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s7"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Use with Erythromycin
</h2>
<p class="First">In patients taking erythromycin, a dose of LIVALO 1 mg once daily should not be exceeded <span class="Italics">[see Drug Interactions (<a href="#s20">7.2</a>)]</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s8"></a><a name="section-2.4"></a><p></p>
<h2>2.4 Use with Rifampin
</h2>
<p class="First">In patients taking rifampin, a dose of LIVALO 2 mg once daily should not be exceeded <span class="Italics">[see Drug Interactions (<a href="#s21">7.3</a>)]</span>.
</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="s9"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS
</h1>
<p class="First">1 mg: Round white film-coated tablet. Debossed â€œKCâ€? on one side and â€œ1â€? on the other side of the tablet.
</p>
<p>2 mg: Round white film-coated tablet. Debossed â€œKCâ€? on one side and â€œ2â€? on the other side of the tablet.
</p>
<p>4 mg: Round white film-coated tablet. Debossed â€œKCâ€? on one side and â€œ4â€? on the other side of the tablet.
</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="s10"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS
</h1>
<p class="First">The use of LIVALO is contraindicated in the following conditions:
</p>
<ul class="Disc">
<li>Patients with a known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to any component of this product. <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span> including <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, and <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> have been reported with LIVALO <span class="Italics">[see Adverse Reactions (<a href="#s16">6.1</a>)]</span>.
</li>
<li>Patients with active liver disease which may include unexplained persistent elevations of hepatic transaminase levels <span class="Italics">[see Warnings and Precautions (<a href="#s13">5.2</a>), Use in Specific Populations (<a href="#s33">8.7</a>)]</span>.
</li>
<li>Women who are pregnant or may become pregnant. Because HMG-CoA reductase inhibitors decrease <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> synthesis and possibly the synthesis of other biologically active substances derived from <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, LIVALO may cause fetal harm when administered to pregnant women. Additionally, there is no apparent benefit to therapy during pregnancy, and safety in pregnant women has not been established. If the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus and the lack of known clinical benefit with continued use during pregnancy <span class="Italics">[seeÂ Use in Specific Populations (<a href="#s27">8.1</a>) and Nonclinical Toxicology (<a href="#s53">13.2</a>)]</span>.
</li>
<li>Nursing mothers. Animal studies have shown that LIVALO passes into breast milk. Since HMG-CoA reductase inhibitors have the potential to cause serious adverse reactions in nursing infants, LIVALO, like other HMG-CoA reductase inhibitors, is contraindicated in pregnant or nursing mothers <span class="Italics">[see Use in Specific Populations (<a href="#s29">8.3</a>) and Nonclinical Toxicology (<a href="#s53">13.2</a>)]</span>.
</li>
<li>Co-administration with cyclosporine <span class="Italics">[see Drug Interactions (<a href="#s19">7.1</a>) and Clinical Pharmacology (<a href="#s39">12.3</a>)].</span>
</li>
</ul>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="s11"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s12"></a><a name="section-5.1"></a><p></p>
<h2>5.1 Skeletal Muscle Effects
</h2>
<p class="First"><span class="Bold">Cases of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> and <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> with <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> secondary to <span class="product-label-link" type="condition" conceptid="439142" conceptname="Myoglobinuria">myoglobinuria</span> have been reported with HMG-CoA reductase inhibitors, including LIVALO.</span> These risks can occur at any dose level, but increase in a dose-dependent manner.
</p>
<p>LIVALO should be prescribed with caution in patients with predisposing factors for <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>. These factors include advanced age (â‰¥65 years), <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, and inadequately treated <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span>. The risk of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> may also be increased with concurrent administration of fibrates or lipid-modifying doses of niacin. LIVALO should be administered with caution in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>, in elderly patients, or when used concomitantly with fibrates or lipid-modifying doses of niacin <span class="Italics">[see Drug Interactions (<a href="#s24">7.6</a>), Use in Specific Populations (<a href="#s31">8.5</a>, <a href="#s32">8.6</a>) and Clinical Pharmacology (<a href="#s39">12.3</a>)].</span></p>
<p>Cases of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>, including <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>, have been reported with HMG-CoA reductase inhibitors coadministered with colchicine, and caution should be exercised when prescribing LIVALO with colchicine [see <span class="Italics">Drug Interactions</span> (<a href="#e25">7.7</a>)].							</p>
<p>There have been rare reports of immune-mediated necrotizing <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> (IMNM), an autoimmune <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>, associated with statin use.Â  IMNM is characterized by: proximal <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span> and elevated serum creatine kinase, which persist despite discontinuation of statin treatment; muscle biopsy showing necrotizing <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> without significant <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>; improvement with immunosuppressive agents.
</p>
<p>LIVALO therapy should be discontinued if markedly elevated creatine kinase (CK) levels occur or <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> is diagnosed or suspected. LIVALO therapy should also be temporarily withheld in any patient with an acute, serious condition suggestive of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> or predisposing to the development of <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> secondary to <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> (e.g., <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, major surgery, <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span>, severe metabolic, endocrine, and electrolyte disorders, or uncontrolled <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>). All patients should be advised to promptly report unexplained <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pain</span>, <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>, or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, particularly if accompanied by <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span> or <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> or if muscle signs and symptoms persist after discontinuing LIVALO.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s13"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Liver Enzyme Abnormalities
</h2>
<p class="First">Increases in serum transaminases (<span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">aspartate aminotransferase</span> [AST]/serum glutamic-oxaloacetic transaminase, or <span class="product-label-link" type="condition" conceptid="4211515" conceptname="Alanine aminotransferase">alanine aminotransferase</span> [ALT]/serum glutamic-pyruvic transaminase) have been reported with HMG-CoA reductase inhibitors, including LIVALO. In most cases, the elevations were transient and resolved or improved on continued therapy or after a brief interruption in therapy.
</p>
<p>In placebo-controlled Phase 2 studies, ALT &gt;3 times the upper limit of normal was not observed in the placebo, LIVALO 1 mg, or LIVALO 2 mg groups. One out of 202 patients (0.5%)Â administered LIVALO 4 mg had ALT &gt;3 timesÂ the upper limit of normal.
</p>
<p>It is recommended that liver enzyme tests be performed before the initiation of LIVALO and if signs or symptoms of <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span> occur.
</p>
<p>There have been rare postmarketing reports of fatal and non-fatal <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span> in patients taking statins, including pitavastatin. If serious <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span> with clinical symptoms and/or <span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">hyperbilirubinemia</span> or <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> occurs during treatment with LIVALO, promptly interrupt therapy. If an alternate etiology is not found do not restart LIVALO.
</p>
<p>As with other HMG-CoA reductase inhibitors, LIVALO should be used with caution in patients who consume substantial quantities of alcohol. Active liver disease, which may include unexplained persistent transaminase elevations, is a contraindication to the use of LIVALO <span class="Italics">[see Contraindications (<a href="#s10">4</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s14"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Endocrine Function
</h2>
<p class="First">Increases in HbA1c and fasting serum glucose levels have been reported with HMG-CoA reductase inhibitors, including LIVALO.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="s15"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS
</h1>
<p class="First">The following serious adverse reactions are discussed in greater detail in other sections of the label:
</p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">Rhabdomyolysis</span> with <span class="product-label-link" type="condition" conceptid="439142" conceptname="Myoglobinuria">myoglobinuria</span> and <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> and <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> (including <span class="product-label-link" type="condition" conceptid="73001" conceptname="Myositis">myositis</span>) <span class="Italics">[see Warnings and Precautions (<a href="#s12">5.1</a>)].</span>
</li>
<li>Liver Enzyme Abnormalities <span class="Italics">[see Warning and Precautions (<a href="#s13">5.2</a>)].</span>
</li>
</ul>
<p>Of 4,798 patients enrolled in 10 controlled clinical studies and 4 subsequent open-label extension studies, 3,291 patients were administered pitavastatin 1 mg to 4 mg daily. The mean continuous exposure of pitavastatin (1 mg to 4 mg) was 36.7 weeks (median 51.1 weeks). The mean age of the patients was 60.9 years (range; 18 years â€“ 89 years) and the gender distribution was 48% males and 52% females. Approximately 93% of the patients were Caucasian, 7% were Asian/Indian, 0.2% were African American and 0.3% were Hispanic and other.
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s16"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Studies Experience
</h2>
<p class="First">Because clinical studies on LIVALO are conducted in varying study populations and study designs, the frequency of adverse reactions observed in the clinical studies of LIVALO cannot be directly compared with that in the clinical studies of other HMG-CoA reductase inhibitors and may not reflect the frequency of adverse reactions observed in clinical practice.
</p>
<p>Adverse reactions reported in
â‰¥ 2% of patients in controlled clinical studies and at a rate greater than or equal to placebo are shown in <a href="#t1">Table 1</a>. These studies had treatment duration of up to 12 weeks.
</p>
<a name="t1"></a><table width="100%">
<caption><span>Table 1.  Adverse Reactions* Reported by â‰¥2.0% of Patients Treated with LIVALO and &gt; Placebo in Short-Term Controlled Studies
</span></caption>
<col align="left" width="16.600%">
<col align="left" width="19.980%">
<col align="left" width="18.940%">
<col align="left" width="23.420%">
<col align="left" width="21.060%">
<tfoot><tr class="First Last"><td align="left" colspan="5" valign="top"><p class="First Footnote">* Adverse reactions by MedDRA preferred term.
</p></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Adverse<br>Reactions*
</td>
<td class="Botrule Rrule Toprule" align="center" valign="bottom">Placebo<br>N= 208<br>
</td>
<td class="Botrule Rrule Toprule" align="center" valign="bottom">LIVALO<br>1 mg<br>N=309
</td>
<td class="Botrule Rrule Toprule" align="center" valign="bottom">LIVALO<br>2Â mg<br>N=951
</td>
<td class="Botrule Rrule Toprule" align="center" valign="bottom">LIVALO<br>4Â mg<br>N=1540
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back Pain</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">2.9%
</td>
<td class="Botrule Rrule" align="center" valign="top">3.9%
</td>
<td class="Botrule Rrule" align="center" valign="top">1.8%
</td>
<td class="Botrule Rrule" align="center" valign="top">1.4%
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">1.9%
</td>
<td class="Botrule Rrule" align="center" valign="top">3.6%
</td>
<td class="Botrule Rrule" align="center" valign="top">1.5%
</td>
<td class="Botrule Rrule" align="center" valign="top">2.2%
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">1.9%
</td>
<td class="Botrule Rrule" align="center" valign="top">2.6%
</td>
<td class="Botrule Rrule" align="center" valign="top">1.5%
</td>
<td class="Botrule Rrule" align="center" valign="top">1.9%
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">1.4%
</td>
<td class="Botrule Rrule" align="center" valign="top">1.9%
</td>
<td class="Botrule Rrule" align="center" valign="top">2.8%
</td>
<td class="Botrule Rrule" align="center" valign="top">3.1%
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">Pain in extremity</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">1.9%
</td>
<td class="Botrule Rrule" align="center" valign="top">2.3%
</td>
<td class="Botrule Rrule" align="center" valign="top">0.6%
</td>
<td class="Botrule Rrule" align="center" valign="top">0.9%
</td>
</tr>
</tbody>
</table>
<p>Other adverse reactions reported from clinical studies were <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">influenza</span>, and <span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">nasopharyngitis</span>.
</p>
<p>The following laboratory abnormalities have also been reported: elevated creatine phosphokinase, transaminases, alkaline phosphatase, bilirubin, and glucose.
</p>
<p>In controlled clinical studies and their open-label extensions, 3.9% (1 mg), 3.3% (2 mg), and 3.7% (4 mg) of pitavastatin-treated patients were discontinued due to adverse reactions. The most common adverse reactions that led to treatment discontinuation were: elevated creatine phosphokinase (0.6% on 4 mg) and <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span> (0.5% on 4 mg).
</p>
<p><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span> including <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, and <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> have been reported with LIVALO.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s17"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Postmarketing Experience
</h2>
<p class="First">The following adverse reactions have been identified during postapproval use of LIVALO. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
</p>
<p>Adverse reactions associated with LIVALO therapy reported since market introduction, regardless of causality assessment, include the following: <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">abdominal discomfort</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, fatal and non-fatal <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">hypoesthesia</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="4119786" conceptname="Interstitial lung disease">interstitial lung disease</span>, <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">erectile dysfunction</span> and <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle spasms</span>.
</p>
<p>There have been rare postmarketing reports of <span class="product-label-link" type="condition" conceptid="443432" conceptname="Impaired cognition">cognitive impairment</span> (e.g., <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">memory loss</span>, <span class="product-label-link" type="condition" conceptid="4304008" conceptname="Memory impairment">forgetfulness</span>, <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">amnesia</span>, <span class="product-label-link" type="condition" conceptid="4304008" conceptname="Memory impairment">memory impairment</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>) associated with statin use. These cognitive issues have been reported for all statins. The reports are generally nonserious, and reversible upon statin discontinuation, with variable times to symptom onset (1 day to years) and symptom resolution (median of 3 weeks).
</p>
<p>There have been rare reports of immune-mediated necrotizing <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> associated with statin use [see <span class="Italics">Warnings and Precautions (<a href="#s12">5.1</a>)</span>].
</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="s18"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s19"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Cyclosporine
</h2>
<p class="First">Cyclosporine significantly increased pitavastatin exposure. Co-administration of cyclosporine with LIVALO is contraindicated [<span class="Italics">see Contraindications (<a href="#s10">4</a>) and Clinical Pharmacology (<a href="#s39">12.3</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s20"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Erythromycin
</h2>
<p class="First">Erythromycin significantly increased pitavastatin exposure. In patients taking erythromycin, a dose of LIVALO 1Â mg once daily should not be exceeded <span class="Italics">[see Dosage and Administration (<a href="#s7">2.3</a>) and Clinical Pharmacology (<a href="#s39">12.3</a>)]</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s21"></a><a name="section-7.3"></a><p></p>
<h2>7.3 Rifampin
</h2>
<p class="First">Rifampin significantly increased pitavastatin exposure.  In patients taking rifampin, a dose of LIVALO 2 mg once daily should not be exceeded <span class="Italics">[see Dosage and Administration (<a href="#s8">2.4</a>) and Clinical Pharmacology (<a href="#s39">12.3</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s22"></a><a name="section-7.4"></a><p></p>
<h2>7.4 Gemfibrozil
</h2>
<p class="First">Due to an increased risk of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>/<span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> when HMG-CoA reductase inhibitors are coadministered with gemfibrozil, concomitant administration of LIVALO with gemfibrozil should be avoided.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s23"></a><a name="section-7.5"></a><p></p>
<h2>7.5 Other Fibrates
</h2>
<p class="First">Because it is known that the risk of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> during treatment with HMG-CoA reductase inhibitors is increased with concurrent administration of other fibrates, LIVALO should be administered with caution when used concomitantly with  other fibrates <span class="Italics">[see Warnings and Precautions (<a href="#s12">5.1</a>), and Clinical Pharmacology (<a href="#s39">12.3</a>)]</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s24"></a><a name="section-7.6"></a><p></p>
<h2>7.6 Niacin
</h2>
<p class="First">The risk of skeletal muscle effects may be enhanced when LIVALO is used in combination with niacin; a reduction in LIVALO dosage should be considered in this setting <span class="Italics">[see Warnings and Precautions (<a href="#s12">5.1</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="e25"></a><a name="section-7.7"></a><p></p>
<h2>7.7 Colchicine
</h2>
<p class="First">Cases of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>, including <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>, have been reported with HMG-CoA reductase inhibitors coadministered with colchicine, and caution should be exercised when prescribing LIVALO with colchicine.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s25"></a><a name="section-7.8"></a><p></p>
<h2>7.8 Warfarin
</h2>
<p class="First">LIVALO had no significant <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interaction</span> with R- and S- warfarin. LIVALO had no significant effect on <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time (PT) and international normalized ratio (INR) when administered to patients receiving chronic warfarin treatment <span class="Italics">[see Clinical Pharmacology (<a href="#s39">12.3</a>)]</span>.  However, patients receiving warfarin should have their PT and INR monitored when pitavastatin is added to their therapy.
</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="s26"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS
</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="s27"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy
</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="s28"></a><a name="section-8.1.1"></a><p></p>
<p class="First"><span class="Bold">Teratogenic effects:  Pregnancy Category X</span></p>
<p>LIVALO is contraindicated in women who are or may become pregnant.  Serum <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> and TG increase during <span class="product-label-link" type="condition" conceptid="4128331" conceptname="Pregnancy">normal pregnancy</span>, and <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> products are essential for fetal development. <span class="product-label-link" type="condition" conceptid="4103842" conceptname="Arteriosclerosis">Atherosclerosis</span> is a chronic process and discontinuation of lipid-lowering drugs during pregnancy should have little impact on long-term outcomes of primary <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span> therapy <span class="Italics">[see Contraindications (<a href="#s10">4</a>)]</span>.
</p>
<p>There are no adequate and well-controlled studies of LIVALO in pregnant women, although, there have been rare reports of congenital anomalies following intrauterine exposure to HMG-CoA reductase inhibitors. In a review of about 100 prospectively followed pregnancies in women exposed to other HMG-CoA reductase inhibitors, the incidences of congenital anomalies, <span class="product-label-link" type="condition" conceptid="4067106" conceptname="Miscarriage">spontaneous abortions</span>, and <span class="product-label-link" type="condition" conceptid="4079844" conceptname="Fetal death">fetal deaths</span>/<span class="product-label-link" type="condition" conceptid="443213" conceptname="Stillbirth">stillbirths</span> did not exceed the rate expected in the general population.  However, this study was only able to exclude a three-to-four-fold increased risk of congenital anomalies over background incidence.  In 89% of these cases, drug treatment started before pregnancy and stopped during the first trimester when pregnancy was identified.
</p>
<p>Reproductive toxicity studies have shown that pitavastatin crosses the placenta in rats and is found in fetal tissues at â‰¤36% of maternal plasma concentrations following a single dose of 1 mg/kg/day during gestation.
</p>
<p>Embryo-fetal developmental studies were conducted in pregnant rats treated with 3, 10, 30 mg/kg/day pitavastatin by oral gavage during organogenesis.  No adverse effects were observed at 3 mg/kg/day, systemic exposures 22 times human systemic exposure at 4 mg/day based on AUC.
</p>
<p>Embryo-fetal developmental studies were conducted in pregnant rabbits treated with 0.1, 0.3, 1 mg/kg/day pitavastatin by oral gavage during the period of fetal organogenesis.  Maternal toxicity consisting of reduced body weight and abortion was observed at all doses tested (4 times human systemic exposure at 4 mg/day based on AUC).
</p>
<p>In perinatal/postnatal studies in pregnant rats given oral gavage doses of pitavastatin at 0.1, 0.3, 1, 3, 10, 30 mg/kg/day from organogenesis through weaning, maternal toxicity consisting of mortality at â‰¥0.3 mg/kg/day and impaired lactation at all doses contributed to the decreased survival of neonates in all dose groups (0.1 mg/kg/day represents approximately 1 time human systemic exposure at 4 mg/day dose based on AUC).
</p>
<p>LIVALO may cause fetal harm when administered to a pregnant woman. If the patient becomes pregnant while taking LIVALO, the patient should be apprised of the potential risks to the fetus and the lack of known clinical benefit with continued use during pregnancy.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="s29"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers
</h2>
<p class="First">It is not known whether pitavastatin is excreted in human milk, however, it has been shown that a small amount of another drug in this class passes into human milk. Rat studies have shown that pitavastatin is excreted into breast milk. Because another drug in this class passes into human milk and HMG-CoA reductase inhibitors have a potential to cause serious adverse reactions in nursing infants, women who require LIVALO treatment should be advised not to nurse their infants or to discontinue LIVALO <span class="Italics">[see Contraindications (<a href="#s10">4</a>)]</span>.
</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="s30"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use
</h2>
<p class="First">Safety and effectiveness of LIVALO in pediatric patients have not been established.
</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="s31"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use
</h2>
<p class="First">Of the 2,800Â patients randomized to LIVALO 1 mg to 4 mg in controlled clinical studies, 1,209Â (43%) were 65Â years and older. No significant differences in efficacy or safety were observed between elderly patients and younger patients. However, greater sensitivity of some older individuals cannot be ruled out.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s32"></a><a name="section-8.5"></a><p></p>
<h2>8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>
</h2>
<p class="First">Patients with moderate and severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (glomerular filtration rate 30Â â€“ 59 mL/min/1.73 m<span class="Sup">2</span> and 15 â€“ 29 mL/min/1.73 m<span class="Sup">2</span> not receiving hemodialysis, respectively) as well as end-stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> receiving hemodialysis should receive a starting dose of LIVALO 1 mg once daily and a maximum dose of LIVALO 2 mg once daily <span class="Italics">[see Dosage and Administration (<a href="#s6">2.2</a>) and Clinical Pharmacology (<a href="#s39">12.3</a>)]</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s33"></a><a name="section-8.6"></a><p></p>
<h2>8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>
</h2>
<p class="First">LIVALO is contraindicated in patients with active liver disease which may include unexplained persistent elevations of hepatic transaminase levels.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="s34"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE
</h1>
<p class="First">There is no known specific treatment in the event of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of pitavastatin. In the event of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, the patient should be treated symptomatically and supportive measures instituted as required. Hemodialysis is unlikely to be of benefit due to high protein binding ratio of pitavastatin.
</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="s35"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION
</h1>
<p class="First">LIVALO (pitavastatin) is an inhibitor of HMG-CoA reductase. It is a synthetic lipid-lowering agent for oral administration.
</p>
<p>The chemical name for pitavastatin is (+)monocalcium <span class="Italics">bis</span>{(3R, 5S, 6<span class="Italics">E</span>)-7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolyl]-3,5-dihydroxy-6-heptenoate}. The structural formula is:
</p>
<div class="Figure">
<a name="f01"></a><img alt="Structural Formula
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=44dcbf97-99ec-427c-ba50-207e0069d6d2&amp;name=liv01-0003-01.jpg">
</div>
<p>The empirical formula for pitavastatin is C<span class="Sub">50</span>H<span class="Sub">46</span>CaF<span class="Sub">2</span>N<span class="Sub">2</span>O<span class="Sub">8</span> and the molecular weight is 880.98. Pitavastatin is odorless and occurs as white to <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span>-yellow powder. It is freely soluble in pyridine, chloroform, dilute hydrochloric acid, and tetrahydrofuran, soluble in ethylene glycol, sparingly soluble in octanol, slightly soluble in methanol, very slightly soluble in water or ethanol, and practically insoluble in acetonitrile or diethyl ether. Pitavastatin is hygroscopic and slightly unstable in light.
</p>
<p>Each film-coated tablet of LIVALO contains 1.045 mg, 2.09 mg, or 4.18 mg of pitavastatin calcium, which is equivalent to 1 mg, 2Â mg, or 4Â mg, respectively of free base and the following inactive ingredients: lactose monohydrate, low substituted hydroxypropylcellulose, hypromellose, magnesium aluminometasilicate, magnesium stearate, and film coating containing the following inactive ingredients: hypromellose, titanium dioxide, triethyl citrate, and colloidal anhydrous silica.
</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="s36"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY
</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="s37"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action
</h2>
<p class="First">Pitavastatin competitively inhibits HMG-CoA reductase, which is a rate-determining enzyme involved with biosynthesis of <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, in a manner of competition with the substrate so that it inhibits <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> synthesis in the liver. As a result, the expression of LDL-receptors followed by the uptake of LDL from blood to liver is accelerated and then the plasma TC decreases. Further, the sustained inhibition of <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> synthesis in the liver decreases levels of very low density lipoproteins.
</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="s38"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics
</h2>
<p class="First">In a randomized, double-blind, placebo-controlled, 4-way parallel, active-comparator study with moxifloxacin in 174 healthy participants, LIVALO was not associated with clinically meaningful prolongation of the QTc interval or heart rate at daily doses up to 16 mg (4 times the recommended maximum daily dose).
</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="s39"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics
</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s40"></a><a name="section-11.3.1"></a><p></p>
<p class="First"><span class="Bold">Absorption:</span> Pitavastatin peak plasma concentrations are achieved about 1 hour after oral administration. Both C<span class="Sub">max</span> and AUC<span class="Sub">0-inf</span> increased in an approximately dose-proportional manner for single LIVALO doses from 1 to 24 mg once daily. The absolute bioavailability of pitavastatin oral solution is 51%. Administration of LIVALO with a high fat meal (50% fat content) decreases pitavastatin C<span class="Sub">max</span>  by 43% but does not significantly reduce pitavastatin AUC. The C<span class="Sub">max</span> and AUC of pitavastatin did not differ following evening or morning drug administration. In healthy volunteers receiving 4 mg pitavastatin, the percent change from baseline for LDL-C following evening dosing was slightly greater than that following morning dosing. Pitavastatin was absorbed in the small intestine but very little in the colon.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s41"></a><a name="section-11.3.2"></a><p></p>
<p class="First"><span class="Bold">Distribution:</span> Pitavastatin is more than 99% protein bound in human plasma, mainly to albumin and alpha 1-acid glycoprotein, and the mean volume of distribution is approximately 148 L.  Association of pitavastatin and/or its metabolites with the blood cells is minimal.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s42"></a><a name="section-11.3.3"></a><p></p>
<p class="First"><span class="Bold">Metabolism:</span> Pitavastatin is marginally metabolized by CYP2C9 and to a lesser extent by CYP2C8. The major metabolite in human plasma is the lactone which is formed via an ester-type pitavastatin glucuronide conjugate by uridine 5'-diphosphate (UDP) glucuronosyltransferase (UGT1A3 and UGT2B7).
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s43"></a><a name="section-11.3.4"></a><p></p>
<p class="First"><span class="Bold">Excretion:</span> A mean of 15% of radioactivity of orally administered,  single 32 mg <span class="Sup">14</span>C-labeled pitavastatin dose was excreted in urine, whereas a mean of 79%  of the dose was excreted in feces within 7 days. The mean plasma elimination half-life is approximately 12 hours.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s44"></a><a name="section-11.3.5"></a><p></p>
<p class="First"><span class="Bold">Race:</span> In pharmacokinetic studies pitavastatin C<span class="Sub">max</span> and AUC were 21 and 5% lower, respectively in Black or African American healthy volunteers compared with those of Caucasian healthy volunteers. In pharmacokinetic comparison between Caucasian volunteers and Japanese volunteers, there were no significant differences in C<span class="Sub">max</span> and AUC.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s45"></a><a name="section-11.3.6"></a><p></p>
<p class="First"><span class="Bold">Gender:</span> In a pharmacokinetic study which compared healthy male and female volunteers, pitavastatin C<span class="Sub">max</span> and AUC were 60 and 54% higher, respectively in females. This had no effect on the efficacy or safety of LIVALO in women in clinical studies.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s46"></a><a name="section-11.3.7"></a><p></p>
<p class="First"><span class="Bold">Geriatric:</span> In a pharmacokinetic study which compared healthy young and elderly (â‰¥65Â years) volunteers, pitavastatin C<span class="Sub">max</span> and AUC were 10 and 30% higher, respectively, in the elderly. This had no effect on the efficacy or safety of LIVALO in elderly subjects in clinical studies.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s47"></a><a name="section-11.3.8"></a><p></p>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>:</span> In patients with moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (glomerular filtration rate of 30 â€“ 59 mL/min/1.73 m<span class="Sup">2</span>) and end stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> receiving hemodialysis, pitavastatin AUC<span class="Sub">0-inf</span> is 102 and 86% higher than those of healthy volunteers, respectively, while pitavastatin C<span class="Sub">max</span> is 60 and 40% higher than those of healthy volunteers, respectively. Patients received hemodialysis immediately before pitavastatin dosing and did not undergo hemodialysis during the pharmacokinetic study. Hemodialysis patients have 33 and 36% increases in the mean unbound fraction of pitavastatin as compared to healthy volunteers and patients with moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, respectively.
</p>
<p>In another pharmacokinetic study, patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (glomerular filtration rate 15 â€“ 29 mL/min/1.73 m<span class="Sup">2</span>) not receiving hemodialysis were administered a single dose of LIVALO 4 mg.  The AUC<span class="Sub">0-inf</span> and the C<span class="Sub">max</span> were 36 and 18% higher, respectively, compared with those of healthy volunteers.  For both patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> and healthy volunteers, the mean percentage of protein-unbound pitavastatin was approximately 0.6%.
</p>
<p>The effect of mild <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> on pitavastatin exposure has not been studied.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s48"></a><a name="section-11.3.9"></a><p></p>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>:</span> The disposition of pitavastatin was compared in healthy volunteers and patients with various degrees of <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. The ratio of pitavastatin C<span class="Sub">max</span> between patients with moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh B disease) and healthy volunteers was 2.7.  The ratio of pitavastatin AUC<span class="Sub">inf</span> between patients with moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> and healthy volunteers was 3.8.  The ratio of pitavastatin C<span class="Sub">max</span> between patients with mild <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh A disease) and healthy volunteers was 1.3.  The ratio of pitavastatin AUC<span class="Sub">inf</span> between patients with mild <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> and healthy volunteers was 1.6.  Mean pitavastatin t<span class="Sub">Â½</span> for moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, mild <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, and healthy were 15, 10, and 8 hours, respectively.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s49"></a><a name="section-11.3.10"></a><p></p>
<p class="First"><span class="Bold">Drug-Drug Interactions:</span> The principal route of pitavastatin metabolism is glucuronidation via liver UGTs with subsequent formation of pitavastatin lactone. There is only minimal metabolism by the cytochrome P450 system.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s50"></a><a name="section-11.3.11"></a><p></p>
<p class="First"><span class="Bold">Warfarin</span>: The steady-state pharmacodynamics (international normalized ratio [INR] and <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time [PT]) and pharmacokinetics of warfarin in healthy volunteers were unaffected by the co-administration of LIVALO 4Â mg daily. However, patients receiving warfarin should have their PT time or INR monitored when pitavastatin is added to their therapy.
</p>
<a name="t2"></a><table width="100%">
<caption><span>Table 2.  Effect of Co-Administered Drugs on Pitavastatin Systemic Exposure
</span></caption>
<col align="left" width="24.825%">
<col align="left" width="43.500%">
<col align="left" width="14.375%">
<col align="left" width="17.300%">
<tfoot>
<tr class="First"><td align="left" colspan="4" valign="top"><p class="First Footnote"><span class="Bold"><span class="Sup">*</span></span>Data presented as x-fold change represent the ratio between co-administration and pitavastatin alone (i.e., 1-fold = no change).  Data presented as % change represent % difference relative to pitavastatin alone (i.e., 0% = no change).
</p></td></tr>
<tr><td align="left" colspan="4" valign="top"><p class="First Footnote">â€  Considered clinically significant <span class="Italics">[see Dosage and Administration (<a href="#s4">2</a>) and Drug Interactions (<a href="#s18">7</a>)]</span></p></td></tr>
<tr class="Last"><td align="left" colspan="4" valign="top"><p class="First Footnote">BID = twice daily; QD = once daily; LA = Long Acting
</p></td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">Co-administered drug
</td>
<td class="Botrule Rrule Toprule" align="center" valign="middle">Dose regimen
</td>
<td class="Botrule Rrule Toprule" align="center" valign="middle">Change in<br>AUC*
</td>
<td class="Botrule Rrule Toprule" align="center" valign="middle">Change in  C<span class="Sub">max*</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">Cyclosporine
</td>
<td class="Botrule Rrule" align="left" valign="middle">Pitavastatin 2 mg QD for 6 days + cyclosporine 2 mg/kg on Day 6
</td>
<td class="Botrule Rrule" align="center" valign="middle">â†‘ 4.6 foldâ€ 
</td>
<td class="Botrule Rrule" align="center" valign="middle">â†‘ 6.6 fold â€ 
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">Erythromycin
</td>
<td class="Botrule Rrule" align="left" valign="middle">Pitavastatin 4 mg single dose on Day 4 + erythromycin 500 mg 4 times daily for 6 days
</td>
<td class="Botrule Rrule" align="center" valign="middle">â†‘ 2.8 fold â€ 
</td>
<td class="Botrule Rrule" align="center" valign="middle">â†‘ 3.6 fold â€ 
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">Rifampin
</td>
<td class="Botrule Rrule" align="left" valign="middle">Pitavastatin 4 mg QD + rifampin 600 mg QD for 5 days
</td>
<td class="Botrule Rrule" align="center" valign="middle">â†‘ 29%
</td>
<td class="Botrule Rrule" align="center" valign="middle">â†‘ 2.0 fold
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">Atazanavir
</td>
<td class="Botrule Rrule" align="left" valign="middle">Pitavastatin 4 mg QD + atazanavir 300 mg daily for 5 days
</td>
<td class="Botrule Rrule" align="center" valign="middle">â†‘ 31%
</td>
<td class="Botrule Rrule" align="center" valign="middle">â†‘ 60%
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">Darunavir/Ritonavir
</td>
<td class="Botrule Rrule" align="left" valign="middle">Pitavastatin 4mg QD on Days 1-5 and 12-16 + darunavir/ritonavir  800mg/100 mg QD on Days 6-16
</td>
<td class="Botrule Rrule" align="center" valign="middle">â†“ 26%
</td>
<td class="Botrule Rrule" align="center" valign="middle">â†“ 4%
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">Lopinavir/Ritonavir
</td>
<td class="Botrule Rrule" align="left" valign="middle">Pitavastatin 4 mg QD on Days 1-5 and 20-24 + lopinavir/ritonavir 400 mg/100 mg BID on Days 9 â€“ 24
</td>
<td class="Botrule Rrule" align="center" valign="middle">â†“ 20%
</td>
<td class="Botrule Rrule" align="center" valign="middle">â†“4 %
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">Gemfibrozil
</td>
<td class="Botrule Rrule" align="left" valign="middle">Pitavastatin 4 mg QD + gemfibrozil 600 mg BID for 7 days
</td>
<td class="Botrule Rrule" align="center" valign="middle">â†‘ 45%
</td>
<td class="Botrule Rrule" align="center" valign="middle">â†‘ 31%
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">Fenofibrate
</td>
<td class="Botrule Rrule" align="left" valign="middle">Pitavastatin 4 mg QD + fenofibrate 160 mg QD for 7 days
</td>
<td class="Botrule Rrule" align="center" valign="middle">â†‘18%
</td>
<td class="Botrule Rrule" align="center" valign="middle">â†‘ 11%
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">Ezetimibe
</td>
<td class="Botrule Rrule" align="left" valign="middle">Pitavastatin 2 mg QD  + ezetimibe 10 mg for 7 days
</td>
<td class="Botrule Rrule" align="center" valign="middle">â†“ 2%
</td>
<td class="Botrule Rrule" align="center" valign="middle">â†“0.2%
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">Enalapril
</td>
<td class="Botrule Rrule" align="left" valign="middle">Pitavastatin 4 mg QD + enalapril 20 mg daily for 5 days
</td>
<td class="Botrule Rrule" align="center" valign="middle">â†‘ 6%
</td>
<td class="Botrule Rrule" align="center" valign="middle">â†“ 7%
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">Digoxin
</td>
<td class="Botrule Rrule" align="left" valign="middle">Pitavastatin 4 mg QD + digoxin 0.25 mg for 7 days
</td>
<td class="Botrule Rrule" align="center" valign="middle">â†‘ 4%
</td>
<td class="Botrule Rrule" align="center" valign="middle">â†“ 9%
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">Diltiazem LA
</td>
<td class="Botrule Rrule" align="left" valign="middle">Pitavastatin 4 mg QD on Days 1-5 and 11-15 and diltiazem LA 240 mg on Days 6-15
</td>
<td class="Botrule Rrule" align="center" valign="middle">â†‘10%
</td>
<td class="Botrule Rrule" align="center" valign="middle">â†‘15%
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">Grapefruit Juice
</td>
<td class="Botrule Rrule" align="left" valign="middle">Pitavastatin 2 mg single dose on Day 3 + grapefruit juice for 4 days
</td>
<td class="Botrule Rrule" align="center" valign="middle">â†‘ 15%
</td>
<td class="Botrule Rrule" align="center" valign="middle">â†“ 12%
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="middle">Itraconazole
</td>
<td class="Botrule Rrule" align="left" valign="middle">Pitavastatin 4 mg single dose on Day 4 + itraconazole 200 mg daily for 5 days
</td>
<td class="Botrule Rrule" align="center" valign="middle">â†“ 23%
</td>
<td class="Botrule Rrule" align="center" valign="middle">â†“ 22%
</td>
</tr>
</tbody>
</table>
<a name="t3"></a><table width="100%">
<caption><span>Table 3.  Effect of Pitavastatin Co-Administration on Systemic Exposure to Other Drugs
</span></caption>
<col align="left" width="25.540%">
<col align="left" width="24.680%">
<col align="left" width="19.920%">
<col align="left" width="14.920%">
<col align="left" width="14.940%">
<tfoot>
<tr class="First"><td align="left" colspan="5" valign="top"><p class="First Footnote">*Data presented as % change represent % difference relative to the investigated drug alone
</p></td></tr>
<tr><td align="left" colspan="5" valign="top"><p class="First Footnote">(i.e., 0% = no change).
</p></td></tr>
<tr class="Last"><td align="left" colspan="5" valign="top"><p class="First Footnote">BID = twice daily; QD = once daily; LA = Long Acting
</p></td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">Co-administered drug
</td>
<td class="Botrule Rrule Toprule" align="center" colspan="2" valign="middle">Dose regimen
</td>
<td class="Botrule Rrule Toprule" align="center" valign="middle">Change in<br>AUC*
</td>
<td class="Botrule Rrule Toprule" align="center" valign="middle">Change in  C<span class="Sub">max</span>*
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">Atazanavir
</td>
<td class="Botrule Rrule" align="left" colspan="2" valign="middle">Pitavastatin 4 mg QD + atazanavir 300 mg daily for 5 days
</td>
<td class="Botrule Rrule" align="center" valign="middle">â†‘ 6%
</td>
<td class="Botrule Rrule" align="center" valign="middle">â†‘ 13%
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">Darunavir
</td>
<td class="Botrule Rrule" align="left" colspan="2" valign="middle">Pitavastatin 4mg QD on Days 1-5 and 12-16 + darunavir/ritonavir  800mg/100 mg QD on Days 6-16
</td>
<td class="Botrule Rrule" align="center" valign="middle">â†‘ 3%
</td>
<td class="Botrule Rrule" align="center" valign="middle">â†‘ 6%
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">Lopinavir
</td>
<td class="Botrule Rrule" align="left" colspan="2" valign="middle">Pitavastatin 4 mg QD on Days 1-5 and 20-24 + lopinavir/ritonavir 400 mg/100 mg BID on Days 9 â€“ 24
</td>
<td class="Botrule Rrule" align="center" valign="middle">â†“ 9%
</td>
<td class="Botrule Rrule" align="center" valign="middle">â†“ 7%
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">Ritonavir
</td>
<td class="Botrule Rrule" align="left" colspan="2" valign="middle">Pitavastatin 4 mg QD on Days 1-5 and 20-24 + lopinavir/ritonavir 400 mg/100 mg BID on Days 9 â€“ 24
</td>
<td class="Botrule Rrule" align="center" valign="middle">â†“ 11%
</td>
<td class="Botrule Rrule" align="center" valign="middle">â†“ 11%
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">Ritonavir
</td>
<td class="Botrule Rrule" align="left" colspan="2" valign="middle">Pitavastatin 4mg QD on Days 1-5 and 12-16 + darunavir/ritonavir  800mg/100 mg QD on Days 6-16
</td>
<td class="Botrule Rrule" align="center" valign="middle">â†‘ 8%
</td>
<td class="Botrule Rrule" align="center" valign="middle">â†‘ 2%
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" rowspan="2" valign="middle">Enalapril
</td>
<td class="Botrule Rrule" align="left" rowspan="2" valign="middle">Pitavastatin 4 mg QD + enalapril 20 mg<br>daily for 5 days
</td>
<td class="Botrule Rrule" align="left" valign="middle">Enalapril
</td>
<td class="Botrule Rrule" align="center" valign="middle">â†‘ 12%
</td>
<td class="Botrule Rrule" align="center" valign="middle">â†‘ 12%
</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="middle">Enalaprilat
</td>
<td class="Botrule Rrule" align="center" valign="middle">â†“ 1%
</td>
<td class="Botrule Rrule" align="center" valign="middle">â†“ 1%
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" rowspan="2" valign="middle">Warfarin
</td>
<td class="Botrule Rrule" align="left" rowspan="2" valign="middle">Individualized maintenance dose of warfarin (2 - 7 mg) for 8 days + pitavastatin 4 mg QD for 9 days
</td>
<td class="Botrule Rrule" align="left" valign="middle">R-warfarin
</td>
<td class="Botrule Rrule" align="center" valign="middle">â†‘ 7%
</td>
<td class="Botrule Rrule" align="center" valign="middle">â†‘ 3%
</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="middle">S-warfarin
</td>
<td class="Botrule Rrule" align="center" valign="middle">â†‘ 6%
</td>
<td class="Botrule Rrule" align="center" valign="middle">â†‘ 3%
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">Ezetimibe
</td>
<td class="Botrule Rrule" align="left" colspan="2" valign="middle">Pitavastatin 2 mg QD  + ezetimibe 10 mg for 7 days
</td>
<td class="Botrule Rrule" align="center" valign="middle">â†‘ 9%
</td>
<td class="Botrule Rrule" align="center" valign="middle">â†‘ 2%
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">Digoxin
</td>
<td class="Botrule Rrule" align="left" colspan="2" valign="middle">Pitavastatin 4 mg QD + digoxin 0.25 mg for 7 days
</td>
<td class="Botrule Rrule" align="center" valign="middle">â†“ 3%
</td>
<td class="Botrule Rrule" align="center" valign="middle">â†“ 4%
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">Diltiazem LA
</td>
<td class="Botrule Rrule" align="left" colspan="2" valign="middle">Pitavastatin 4 mg QD on Days 1-5 and 11-15 and diltiazem LA 240 mg on Days 6-15
</td>
<td class="Botrule Rrule" align="center" valign="middle">â†“ 2%
</td>
<td class="Botrule Rrule" align="center" valign="middle">â†“ 7%
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="middle">Rifampin
</td>
<td class="Botrule Rrule" align="left" colspan="2" valign="middle">Pitavastatin 4 mg QD + rifampin 600 mg QD for 5 days
</td>
<td class="Botrule Rrule" align="center" valign="middle">â†“ 15%
</td>
<td class="Botrule Rrule" align="center" valign="middle">â†“ 18%
</td>
</tr>
</tbody>
</table>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="s51"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY
</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="s52"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
</h2>
<p class="First">In a 92-week carcinogenicity study in mice given pitavastatin, at the maximum tolerated dose of 75Â mg/kg/day with systemic maximum exposures (AUC) 26 times the clinical maximum exposure at 4 mg/day, there was an absence of drug-related tumors.
</p>
<p>In a 92-week carcinogenicity study in rats given pitavastatin at 1, 5, 25 mg/kg/day by oral gavage there was a significant increase in the incidence of thyroid follicular cell tumors at 25Â mg/kg/day, which represents 295 times human systemic exposures based on AUC at the 4 mg/day maximum human dose.
</p>
<p>In a 26-week transgenic mouse (Tg rasH2) carcinogenicity study where animals were given pitavastatin at 30, 75, and 150 mg/kg/day by oral gavage, no clinically significant tumors were observed.
</p>
<p>Pitavastatin was not mutagenic in the Ames test with <span class="Italics"><span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> typhimurium</span> and <span class="Italics">Escherichia coli</span> with and without metabolic activation, the micronucleus test following a single administration in mice and multiple administrations in rats, the unscheduled DNA synthesis test in rats, and a Comet assay in mice. In the chromosomal aberration test, clastogenicity was observed at the highest doses tested which also elicited high levels of cytotoxicity.
</p>
<p>Pitavastatin had no adverse effects on male and female rat fertility at oral doses of 10 and 30 mg/kg/day, respectively, at systemic exposures 56- and 354-times clinical exposure at 4 mg/day based on AUC.
</p>
<p>Pitavastatin treatment in rabbits resulted in mortality in males and females given 1 mg/kg/day (30-times clinical systemic exposure at 4 mg/day based on AUC) and higher during a fertility study.  Although the cause of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> was not determined, rabbits had gross signs of renal toxicity (kidneys whitened) indicative of possible <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span>.  Lower doses (15-times human systemic exposure) did not show significant toxicity in adult males and females.  However, decreased implantations, increased resorptions, and decreased viability of fetuses were observed.
</p>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="s53"></a><a name="section-12.2"></a><p></p>
<h2>13.2 Animal Toxicology and/or Pharmacology
</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s54"></a><a name="section-12.2.1"></a><p></p>
<p class="First"><span class="Bold">Central Nervous System Toxicity</span></p>
<p>CNS vascular lesions, characterized by perivascular <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhages</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, and mononuclear cell infiltration of perivascular spaces, have been observed in dogs treated with several other members of this drug class. A chemically similar drug in this class produced dose-dependent optic nerve degeneration (Wallerian degeneration of retinogeniculate fibers) in dogs, at a dose that produced plasma drug levels about 30 times higher than the mean drug level in humans taking the highest recommended dose. Wallerian degeneration has not been observed with pitavastatin.  <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">Cataracts</span> and lens opacities were seen in dogs treated for 52Â weeks at a dose level of 1Â mg/kg/day (9 times clinical exposure at the maximum human dose of 4 mg/day based on AUC comparisons.
</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="s55"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s56"></a><a name="section-13.1"></a><p></p>
<h2>14.1 Primary <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">Hyperlipidemia</span> or Mixed <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">Dyslipidemia</span>
</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s57"></a><a name="section-13.1.1"></a><p></p>
<p class="First"><span class="Italics">Dose-ranging study:</span> A multicenter, randomized, double-blind, placebo-controlled, dose-ranging study was performed to evaluate the efficacy of LIVALO compared with placebo in 251 patients with primary <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span> (<a href="#t4">Table 4</a>). LIVALO given as a single daily dose for 12 weeks significantly reduced plasma LDL-C, TC, TG, and Apo-B compared to placebo and was associated with variable increases in HDL-C across the dose range.
</p>
<a name="t4"></a><table width="100%">
<caption><span>Table 4.  Dose-Response in Patients with Primary <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">Hypercholesterolemia</span> (Adjusted  Mean % Change from Baseline at Week 12)
</span></caption>
<col align="left" width="22.000%">
<col align="left" width="8.100%">
<col align="left" width="14.486%">
<col align="left" width="14.229%">
<col align="left" width="13.243%">
<col align="left" width="13.314%">
<col align="left" width="14.629%">
<tfoot><tr class="First Last"><td align="left" colspan="7" valign="top"><p class="First Footnote"># The number of subjects for Apo-B was 49
</p></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Toprule" align="center" valign="middle">Treatment
</td>
<td class="Botrule Toprule" align="center" valign="middle">N
</td>
<td class="Botrule Toprule" align="center" valign="middle">LDL-C
</td>
<td class="Botrule Toprule" align="center" valign="middle">Apo-B
</td>
<td class="Botrule Toprule" align="center" valign="middle">TC
</td>
<td class="Botrule Toprule" align="center" valign="middle">TG
</td>
<td class="Botrule Toprule" align="center" valign="middle">HDL-C
</td>
</tr>
<tr>
<td align="center" valign="middle">Placebo
</td>
<td align="center" valign="middle">53
</td>
<td align="center" valign="middle">-3
</td>
<td align="center" valign="middle">-2
</td>
<td align="center" valign="middle">-2
</td>
<td align="center" valign="middle">1
</td>
<td align="center" valign="middle">0
</td>
</tr>
<tr>
<td align="center" valign="middle">LIVALO 1mg
</td>
<td align="center" valign="middle">52
</td>
<td align="center" valign="middle">-32
</td>
<td align="center" valign="middle">-25
</td>
<td align="center" valign="middle">-23
</td>
<td align="center" valign="middle">-15
</td>
<td align="center" valign="middle">8
</td>
</tr>
<tr>
<td align="center" valign="middle">LIVALO 2mg
</td>
<td align="center" valign="middle">49
</td>
<td align="center" valign="middle">-36
</td>
<td align="center" valign="middle">-30
</td>
<td align="center" valign="middle">-26
</td>
<td align="center" valign="middle">-19
</td>
<td align="center" valign="middle">7
</td>
</tr>
<tr class="Last">
<td class="Botrule" align="center" valign="middle">LIVALO 4mg
</td>
<td class="Botrule" align="center" valign="middle">51<span class="Sup">#</span>
</td>
<td class="Botrule" align="center" valign="middle">-43
</td>
<td class="Botrule" align="center" valign="middle">-35
</td>
<td class="Botrule" align="center" valign="middle">-31
</td>
<td class="Botrule" align="center" valign="middle">-18
</td>
<td class="Botrule" align="center" valign="middle">5
</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s58"></a><a name="section-13.1.2"></a><p></p>
<p class="First"><span class="Italics">Active-controlled study with atorvastatin (NK-104-301):</span> LIVALO was compared with the HMG-CoA reductase inhibitor atorvastatin in a randomized, multicenter, double-blind, double-dummy, active-controlled, non-inferiority Phase 3 study of 817 patients with primary <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span> or mixed <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">dyslipidemia</span>. Patients entered a 6-Â to 8-week wash-out/dietary lead-in period and then were randomized to a 12-week treatment with either LIVALO or atorvastatin (<a href="#t5">Table 5</a>). Non-inferiority of pitavastatin to a given dose of atorvastatin was considered to be demonstrated if the lower bound of the 95% CI for the mean treatment difference was greater than 6% for the mean percent change in LDL-C.
</p>
<p>Lipid results are shown in <a href="#t5">Table 5</a>.  For the percent change from baseline to endpoint in LDL-C, LIVALO was non-inferior to atorvastatin for the two pairwise comparisons: LIVALO 2 mg vs. atorvastatin 10 mg and LIVALO 4 mg vs. atorvastatin 20 mg. Mean treatment differences (95% CI) were 0% (-3%, 3%) and 1% (-2%, 4%), respectively.
</p>
<a name="t5"></a><table width="100%">
<caption><span>Table 5.  Response by Dose of LIVALO and Atorvastatin in Patients with Primary <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">Hyperlipidemia</span> or Mixed <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">Dyslipidemia</span> (Mean % Change from Baseline at Week 12)
</span></caption>
<col align="left" width="17.163%">
<col align="left" width="9.463%">
<col align="left" width="11.375%">
<col align="left" width="12.925%">
<col align="left" width="10.963%">
<col align="left" width="12.225%">
<col align="left" width="12.175%">
<col align="left" width="13.713%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Toprule" align="center" valign="middle">Treatment
</td>
<td class="Botrule Toprule" align="center" valign="middle">N
</td>
<td class="Botrule Toprule" align="center" valign="middle">LDL-C
</td>
<td class="Botrule Toprule" align="center" valign="middle">Apo-B
</td>
<td class="Botrule Toprule" align="center" valign="middle">TC
</td>
<td class="Botrule Toprule" align="center" valign="middle">TG
</td>
<td class="Botrule Toprule" align="center" valign="middle">HDL-C
</td>
<td class="Botrule Toprule" align="center" valign="middle">non-HDL-C
</td>
</tr>
<tr>
<td align="center" valign="middle">LIVALO<br>2 mg daily
</td>
<td align="center" valign="middle">315
</td>
<td align="center" valign="middle">-38
</td>
<td align="center" valign="middle">-30
</td>
<td align="center" valign="middle">-28
</td>
<td align="center" valign="middle">-14
</td>
<td align="center" valign="middle">4
</td>
<td align="center" valign="middle">-35
</td>
</tr>
<tr>
<td align="center" valign="middle">LIVALO <br>4 mg daily
</td>
<td align="center" valign="middle">298
</td>
<td align="center" valign="middle">-45
</td>
<td align="center" valign="middle">-35
</td>
<td align="center" valign="middle">-32
</td>
<td align="center" valign="middle">-19
</td>
<td align="center" valign="middle">5
</td>
<td align="center" valign="middle">-41
</td>
</tr>
<tr>
<td align="center" valign="middle">Atorvastatin <br>10 mg daily
</td>
<td align="center" valign="middle">102
</td>
<td align="center" valign="middle">-38
</td>
<td align="center" valign="middle">-29
</td>
<td align="center" valign="middle">-28
</td>
<td align="center" valign="middle">-18
</td>
<td align="center" valign="middle">3
</td>
<td align="center" valign="middle">-35
</td>
</tr>
<tr>
<td class="Botrule" align="center" valign="middle">Atorvastatin <br>20 mg daily
</td>
<td class="Botrule" align="center" valign="middle">102
</td>
<td class="Botrule" align="center" valign="middle">-44
</td>
<td class="Botrule" align="center" valign="middle">-36
</td>
<td class="Botrule" align="center" valign="middle">-33
</td>
<td class="Botrule" align="center" valign="middle">-22
</td>
<td class="Botrule" align="center" valign="middle">2
</td>
<td class="Botrule" align="center" valign="middle">-41
</td>
</tr>
<tr class="Last">
<td class="Botrule" align="center" valign="middle">Atorvastatin<br>40 mg daily<br>Atorvastatin<br>80 mg daily
</td>
<td class="Botrule" align="center" colspan="7" valign="middle">
<br>-----------------------------------------Not Studied----------------------------------------------------------<br><br>----------------------------------------Not Studied---------------------------------------------------------
</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s59"></a><a name="section-13.1.3"></a><p></p>
<p class="First"><span class="Italics">Active-controlled study with simvastatin (NK-104-302):</span> LIVALO was compared with the HMG-CoA reductase inhibitor simvastatin in a randomized, multicenter, double-blind, double-dummy, active-controlled, non-inferiority Phase 3 study of 843 patients with primary <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span> or mixed <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">dyslipidemia</span>. Patients entered a 6-Â to 8-week wash-out/dietary lead-in period and then were randomized to a 12Â week treatment with either LIVALO or simvastatin (<a href="#t6">Table 6</a>). Non-inferiority of pitavastatin to a given dose of simvastatin was considered to be demonstrated if the lower bound of the 95% CI for the mean treatment difference was greater than 6% for the mean percent change in LDL-C.
</p>
<p>Lipid results are shown in <a href="#t6">Table 6</a>.  For the percent change from baseline to endpoint in LDL-C, LIVALO was non-inferior to simvastatin for the two pairwise comparisons: LIVALO 2 mg vs. simvastatin 20 mg and LIVALO 4 mg vs. simvastatin 40 mg. Mean treatment differences (95% CI) were 4% (1%, 7%) and 1% (-2%, 4%), respectively.
</p>
<a name="t6"></a><table width="100%">
<caption><span>Table 6.  Response by Dose of LIVALO and Simvastatin in Patients with Primary <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">Hyperlipidemia</span> or Mixed <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">Dyslipidemia</span> (Mean % Change from Baseline at Week 12)
</span></caption>
<col align="left" width="15.687%">
<col align="left" width="9.700%">
<col align="left" width="12.275%">
<col align="left" width="12.275%">
<col align="left" width="12.300%">
<col align="left" width="12.325%">
<col align="left" width="12.262%">
<col align="left" width="13.175%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Toprule" align="center" valign="middle">Treatment
</td>
<td class="Botrule Toprule" align="center" valign="middle">N
</td>
<td class="Botrule Toprule" align="center" valign="middle">LDL-C
</td>
<td class="Botrule Toprule" align="center" valign="middle">Apo-B
</td>
<td class="Botrule Toprule" align="center" valign="middle">TC
</td>
<td class="Botrule Toprule" align="center" valign="middle">TG
</td>
<td class="Botrule Toprule" align="center" valign="middle">HDL-C
</td>
<td class="Botrule Toprule" align="center" valign="middle">non-HDL-C
</td>
</tr>
<tr>
<td align="center" valign="middle">LIVALO<br>2 mg daily
</td>
<td align="center" valign="middle">307
</td>
<td align="center" valign="middle">-39
</td>
<td align="center" valign="middle">-30
</td>
<td align="center" valign="middle">-28
</td>
<td align="center" valign="middle">-16
</td>
<td align="center" valign="middle">6
</td>
<td align="center" valign="middle">-36
</td>
</tr>
<tr>
<td align="center" valign="middle">LIVALO<br>4 mg daily
</td>
<td align="center" valign="middle">319
</td>
<td align="center" valign="middle">-44
</td>
<td align="center" valign="middle">-35
</td>
<td align="center" valign="middle">-32
</td>
<td align="center" valign="middle">-17
</td>
<td align="center" valign="middle">6
</td>
<td align="center" valign="middle">-41
</td>
</tr>
<tr>
<td align="center" valign="middle">Simvastatin <br>20 mg daily
</td>
<td align="center" valign="middle">107
</td>
<td align="center" valign="middle">-35
</td>
<td align="center" valign="middle">-27
</td>
<td align="center" valign="middle">-25
</td>
<td align="center" valign="middle">-16
</td>
<td align="center" valign="middle">6
</td>
<td align="center" valign="middle">-32
</td>
</tr>
<tr>
<td class="Botrule" align="center" valign="middle">Simvastatin <br>40 mg daily
</td>
<td class="Botrule" align="center" valign="middle">110
</td>
<td class="Botrule" align="center" valign="middle">-43
</td>
<td class="Botrule" align="center" valign="middle">-34
</td>
<td class="Botrule" align="center" valign="middle">-31
</td>
<td class="Botrule" align="center" valign="middle">-16
</td>
<td class="Botrule" align="center" valign="middle">7
</td>
<td class="Botrule" align="center" valign="middle">-39
</td>
</tr>
<tr class="Last">
<td class="Botrule" align="center" valign="middle">Simvastatin<br>80 mg
</td>
<td class="Botrule" align="center" colspan="7" valign="middle">---------------------------------------Not Studied------------------------------------------------------------
</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s60"></a><a name="section-13.1.4"></a><p></p>
<p class="First"><span class="Italics">Active-controlled study with pravastatin in elderly (NK-104-306):</span> LIVALO was compared with the HMG-CoA reductase inhibitor pravastatin in a randomized, multicenter, double-blind, double-dummy, parallel group, active-controlled non-inferiority Phase 3 study of 942Â elderly patients (â‰¥65Â years) with primary <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span> or mixed <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">dyslipidemia</span>. Patients entered a 6- to 8-week wash-out/dietary lead-in period, and then were randomized to a once daily dose of LIVALO or pravastatin for 12 weeks (<a href="#t7">Table 7</a>). Non-inferiority of LIVALO to a given dose of pravastatin was assumed if the lower bound of the 95% CI for the treatment difference was greater than -6% for the mean percent change in LDL-C.
</p>
<p>Lipid results are shown in <a href="#t7">Table 7</a>.  LIVALO significantly reduced LDL-C compared to pravastatin as demonstrated by the following pairwise dose comparisons: LIVALO 1 mg vs. pravastatin 10 mg, LIVALO 2 mg vs. pravastatin 20 mg and LIVALO 4 mg vs. pravastatin 40 mg.  Mean treatment differences (95% CI) were 9% (6%, 12%), 10% (7%, 13%) and 10% (7%, 13% ), respectively.
</p>
<a name="t7"></a><table width="100%">
<caption><span>Table 7.  Response by Dose of LIVALO and Pravastatin in Patients with Primary <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">Hyperlipidemia</span> or Mixed <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">Dyslipidemia</span> (Mean % Change from Baseline at Week 12)
</span></caption>
<col align="left" width="16.117%">
<col align="left" width="8.327%">
<col align="left" width="12.678%">
<col align="left" width="12.678%">
<col align="left" width="12.641%">
<col align="left" width="11.940%">
<col align="left" width="12.603%">
<col align="left" width="13.016%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule" align="center" valign="middle">Treatment
</td>
<td class="Botrule" align="center" valign="middle">N
</td>
<td class="Botrule" align="center" valign="middle">LDL-C
</td>
<td class="Botrule" align="center" valign="middle">Apo-B
</td>
<td class="Botrule" align="center" valign="middle">TC
</td>
<td class="Botrule" align="center" valign="middle">TG
</td>
<td class="Botrule" align="center" valign="middle">HDL-C
</td>
<td class="Botrule" align="center" valign="middle">non-HDL-C
</td>
</tr>
<tr>
<td align="center" valign="middle">LIVALO<br>1 mg daily
</td>
<td align="center" valign="middle">207
</td>
<td align="center" valign="middle">-31
</td>
<td align="center" valign="middle">-25
</td>
<td align="center" valign="middle">-22
</td>
<td align="center" valign="middle">-13
</td>
<td align="center" valign="middle">1
</td>
<td align="center" valign="middle">-29
</td>
</tr>
<tr>
<td align="center" valign="middle">LIVALO<br>2 mg daily
</td>
<td align="center" valign="middle">224
</td>
<td align="center" valign="middle">-39
</td>
<td align="center" valign="middle">-31
</td>
<td align="center" valign="middle">-27
</td>
<td align="center" valign="middle">-15
</td>
<td align="center" valign="middle">2
</td>
<td align="center" valign="middle">-36
</td>
</tr>
<tr>
<td align="center" valign="middle">LIVALO <br>4 mg daily
</td>
<td align="center" valign="middle">210
</td>
<td align="center" valign="middle">-44
</td>
<td align="center" valign="middle">-37
</td>
<td align="center" valign="middle">-31
</td>
<td align="center" valign="middle">-22
</td>
<td align="center" valign="middle">4
</td>
<td align="center" valign="middle">-41
</td>
</tr>
<tr>
<td align="center" valign="middle">Pravastatin <br>10 mg daily
</td>
<td align="center" valign="middle">103
</td>
<td align="center" valign="middle">-22
</td>
<td align="center" valign="middle">-17
</td>
<td align="center" valign="middle">-15
</td>
<td align="center" valign="middle">-5
</td>
<td align="center" valign="middle">0
</td>
<td align="center" valign="middle">-20
</td>
</tr>
<tr>
<td align="center" valign="middle">Pravastatin <br>20 mg daily
</td>
<td align="center" valign="middle">96
</td>
<td align="center" valign="middle">-29
</td>
<td align="center" valign="middle">-22
</td>
<td align="center" valign="middle">-21
</td>
<td align="center" valign="middle">-11
</td>
<td align="center" valign="middle">-1
</td>
<td align="center" valign="middle">-27
</td>
</tr>
<tr>
<td class="Botrule" align="center" valign="middle">Pravastatin <br>40 mg daily
</td>
<td class="Botrule" align="center" valign="middle">102
</td>
<td class="Botrule" align="center" valign="middle">-34
</td>
<td class="Botrule" align="center" valign="middle">-28
</td>
<td class="Botrule" align="center" valign="middle">-24
</td>
<td class="Botrule" align="center" valign="middle">-15
</td>
<td class="Botrule" align="center" valign="middle">1
</td>
<td class="Botrule" align="center" valign="middle">-32
</td>
</tr>
<tr class="Last">
<td class="Botrule" align="center" valign="middle">Pravastatin<br>80 mg daily
</td>
<td class="Botrule" align="center" colspan="7" valign="middle">
<br>--------------------------------------Not Studied------------------------------------------------------------
</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s61"></a><a name="section-13.1.5"></a><p></p>
<p class="First"><span class="Italics">Active-controlled study with simvastatin in patients with â‰¥ 2 risk factors for coronary heart disease (NK-104-304):</span> LIVALO was compared with the HMG-CoA reductase inhibitor simvastatin in a randomized, multicenter, double-blind, double-dummy, active-controlled, non-inferiority Phase 3 study of 351 patients with primary <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span> or mixed <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">dyslipidemia</span> with â‰¥2 risk factors for coronary heart disease. After a 6-Â to 8-week wash-out/dietary lead-in period, patients were randomized to a 12-week treatment with either LIVALO or simvastatin (<a href="#t8">Table 8</a>). Non-inferiority of LIVALO to simvastatin was considered to be demonstrated if the lower bound of the 95% CI for the mean treatment difference was greater than -6% for the mean percent change in LDL-C.
</p>
<p>Lipid results are shown in <a href="#t8">Table 8</a>.  LIVALO 4 mg was non-inferior to simvastatin 40 mg for percent change from baseline to endpoint in LDL-C.  The mean treatment difference (95% CI) was 0% (-2%, 3%).
</p>
<a name="t8"></a><table width="100%">
<caption><span>Table 8.  Response by Dose of LIVALO and Simvastatin in Patients with Primary <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">Hyperlipidemia</span> or Mixed <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">Dyslipidemia</span> with â‰¥2 Risk Factors for Coronary Heart Disease (Mean % Change from Baseline at Week 12)
</span></caption>
<col align="left" width="17.417%">
<col align="left" width="6.727%">
<col align="left" width="11.790%">
<col align="left" width="13.266%">
<col align="left" width="11.278%">
<col align="left" width="11.365%">
<col align="left" width="11.740%">
<col align="left" width="16.417%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Toprule" align="center" valign="middle">Treatment
</td>
<td class="Botrule Toprule" align="center" valign="middle">N
</td>
<td class="Botrule Toprule" align="center" valign="middle">LDL-C
</td>
<td class="Botrule Toprule" align="center" valign="middle">Apo-B
</td>
<td class="Botrule Toprule" align="center" valign="middle">TC
</td>
<td class="Botrule Toprule" align="center" valign="middle">TG
</td>
<td class="Botrule Toprule" align="center" valign="middle">HDL-C
</td>
<td class="Botrule Toprule" align="center" valign="middle">non-HDL-C
</td>
</tr>
<tr>
<td align="center" valign="middle">LIVALO<br>4 mg daily
</td>
<td align="center" valign="middle">233
</td>
<td align="center" valign="middle">-44
</td>
<td align="center" valign="middle">-34
</td>
<td align="center" valign="middle">-31
</td>
<td align="center" valign="middle">-20
</td>
<td align="center" valign="middle">7
</td>
<td align="center" valign="middle">-40
</td>
</tr>
<tr>
<td class="Botrule" align="center" valign="middle">Simvastatin <br>40 mg daily
</td>
<td class="Botrule" align="center" valign="middle">118
</td>
<td class="Botrule" align="center" valign="middle">-44
</td>
<td class="Botrule" align="center" valign="middle">-34
</td>
<td class="Botrule" align="center" valign="middle">-31
</td>
<td class="Botrule" align="center" valign="middle">-15
</td>
<td class="Botrule" align="center" valign="middle">5
</td>
<td class="Botrule" align="center" valign="middle">-39
</td>
</tr>
<tr class="Last">
<td class="Botrule" align="center" valign="middle">Simvastatin<br>80 mg daily
</td>
<td class="Botrule" align="center" colspan="7" valign="middle">
<br>--------------------------------------Not Studied--------------------------------------------------------------
</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s62"></a><a name="section-13.1.6"></a><p></p>
<p class="First"><span class="Italics">Active-controlled study with atorvastatin in patients with type II <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus (NK-104-305):</span>  LIVALO was compared with the HMG-CoA reductase inhibitor atorvastatin in a randomized, multicenter, double-blind, double-dummy, parallel group, active-controlled, non-inferiority Phase 3 study of 410 subjects with type II <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus and combined <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">dyslipidemia</span>.  Patients entered a 6- to 8-week washout/dietary lead-in period and were randomized to a once daily dose of LIVALO or atorvastatin for 12 weeks.  Non-inferiority of LIVALO was considered to be demonstrated if the lower bound of the 95% CI for the mean treatment difference was greater than -6% for the mean percent change in LDL-C.
</p>
<p>Lipid results are shown in <a href="#t9">Table 9</a>.  The treatment difference (95% CI) for LDL-C percent change from baseline was -2% (-6.2%, 1.5%).  The two treatment groups were not statistically different on LDL-C.  However, the lower limit of the CI was -6.2%, slightly exceeding the -6% non-inferiority limit so that the non-inferiority objective was not achieved.
</p>
<a name="t9"></a><table width="100%">
<caption><span>Table 9.  Response by Dose of LIVALO and Atorvastatin in Patients with Type II <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> Mellitus and  Combined <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">Dyslipidemia</span> (Mean % Change from Baseline at Week 12)
</span></caption>
<col align="left" width="15.227%">
<col align="left" width="10.014%">
<col align="left" width="12.014%">
<col align="left" width="12.014%">
<col align="left" width="12.014%">
<col align="left" width="12.014%">
<col align="left" width="12.014%">
<col align="left" width="14.689%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Toprule" align="left" valign="top">Treatment
</td>
<td class="Botrule Toprule" align="center" valign="top">N
</td>
<td class="Botrule Toprule" align="center" valign="top">LDL-C
</td>
<td class="Botrule Toprule" align="center" valign="top">Apo-B
</td>
<td class="Botrule Toprule" align="center" valign="top">TC
</td>
<td class="Botrule Toprule" align="center" valign="top">TG
</td>
<td class="Botrule Toprule" align="center" valign="top">HDL-C
</td>
<td class="Botrule Toprule" align="center" valign="top">non-HDL-C
</td>
</tr>
<tr>
<td align="left" valign="top">LIVALO<br>4 mg daily
</td>
<td align="center" valign="top">274
</td>
<td align="center" valign="top">-41
</td>
<td align="center" valign="top">-32
</td>
<td align="center" valign="top">-28
</td>
<td align="center" valign="top">-20
</td>
<td align="center" valign="top">7
</td>
<td align="center" valign="top">-36
</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Atorvastatin<br>20Â mg daily
</td>
<td class="Botrule" align="center" valign="top">136
</td>
<td class="Botrule" align="center" valign="top">-43
</td>
<td class="Botrule" align="center" valign="top">-34
</td>
<td class="Botrule" align="center" valign="top">-32
</td>
<td class="Botrule" align="center" valign="top">-27
</td>
<td class="Botrule" align="center" valign="top">8
</td>
<td class="Botrule" align="center" valign="top">-40
</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Atorvastatin 40 mg daily
</td>
<td class="Botrule" align="left" colspan="7" valign="top">-----------------------------------Not Studied----------------------------------------------------------
</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="top">Atorvastatin 80 mg daily
</td>
<td class="Botrule" align="left" colspan="7" valign="top">-----------------------------------Not Studied----------------------------------------------------------
</td>
</tr>
</tbody>
</table>
<p>TheÂ treatment differencesÂ inÂ efficacy inÂ LDL-C change from baseline between LIVALO and active controls in the Phase 3 studies are summarized in <a href="#fig1">Figure 1</a>.
</p>
<p><a name="fig1"></a><span class="Bold">Figure 1.  Treatment Difference in Adjusted Mean Percent Change in LDL-C</span></p>
<p><a name="f02"></a><img alt="Figure 1
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=44dcbf97-99ec-427c-ba50-207e0069d6d2&amp;name=liv01-0003-02.jpg"></p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="s63"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING
</h1>
<p class="First">LIVALO tablets for oral administration are provided as white, film-coated tablets that contain 1 mg, 2 mg, or 4 mg of pitavastatin. Each tablet has â€œKCâ€? debossed on one side and a code number specific to the tablet strength on the other.
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s64"></a><a name="section-14.1"></a><p></p>
<p class="First"><span class="Bold">Packaging</span></p>
<p>LIVALO (pitavastatin) Tablets are supplied as;
</p>
<ul class="Disc">
<li>NDC 66869-104-90 : 1 mg. Round white film-coated tablet debossed â€œKCâ€? on one face and â€œ1â€? on the reverse; HDPE bottles of 90Â tablets
</li>
<li>NDC 66869-204-90 : 2 mg. Round white film-coated tablet debossed â€œKCâ€? on one face and â€œ2â€? on the reverse; HDPE bottles of 90Â tablets
</li>
<li>NDC 66869-404-90 : 4 mg. Round white film-coated tablet debossed â€œKCâ€? on one face and â€œ4â€? on the reverse; HDPE bottles of 90Â tablets
</li>
</ul>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="s65"></a><a name="section-14.2"></a><p></p>
<p class="First"><span class="Bold">Storage</span></p>
<p>Store at room temperature between 15Â°C and 30Â°C (59Â° to 86Â° F) [see USP]. Protect from light.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="s66"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION
</h1>
<p class="First">The patient should be informed of the following:
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s67"></a><a name="section-15.1"></a><p></p>
<h2>17.1 Dosing Time
</h2>
<p class="First">LIVALO can be taken at any time of the day with or without food.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s68"></a><a name="section-15.2"></a><p></p>
<h2>17.2 <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Muscle Pain</span>
</h2>
<p class="First">Patients should be advised to promptly notify their physician of any unexplained <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pain</span>, <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>, or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> particularly if accompanied by <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span> or <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, or if these muscle signs or symptoms persist after discontinuing LIVALO. They should discuss all medication, both prescription and over the counter, with their physician.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s69"></a><a name="section-15.3"></a><p></p>
<h2>17.3 Pregnancy
</h2>
<p class="First">Women of childbearing age should use an effective method of birth control to prevent pregnancy while using LIVALO. Discuss future pregnancy plans with your healthcare professional, and discuss when to stop LIVALO if you are trying to conceive. If you are pregnant, stop taking LIVALO and call your healthcare professional.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s70"></a><a name="section-15.4"></a><p></p>
<h2>17.4 Breastfeeding
</h2>
<p class="First">Women who are breastfeeding should not use LIVALO. If you have a lipid disorder and are breastfeeding, stop taking LIVALO and consult with your healthcare professional.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s71"></a><a name="section-15.5"></a><p></p>
<h2>17.5 Liver Enzymes
</h2>
<p class="First">It is recommended that liver enzyme tests be checked before the initiation of LIVALO and if signs or symptoms of <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span> occur.   All patients treated with LIVALO should be advised to report promptly any symptoms that may indicate <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span>, including <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, right <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">upper abdominal discomfort</span>, dark urine or <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>.
</p>
<p>LIVALO is a trademark of the Kowa group of companies.
</p>
<p>Â© Kowa Pharmaceuticals America, Inc.Â  (2009)
</p>
<p>Manufactured under license from: Kowa Company, Limited Tokyo 103-8433 Japan<br>Product of Japan<br>Manufactured into tablets by: Patheon, Inc. Cincinnati, OH 45237 USA or by Kowa Company, LTD Nagoya, 462-0024 Japan<br>Marketed by: Kowa Pharmaceuticals America, Inc. Montgomery, AL 36117 USA<br>To request additional information or if you have questions concerning LIVALO please phone Kowa Pharmaceuticals America, Inc. at 877-8-LIVALO (877-854-8256) or fax your inquiry to 800-689-0244
</p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s72"></a><a name="section-16"></a><p></p>
<p class="First"><span class="Bold">Principal Display Panel - Bottle Label Livalo 1 mg</span></p>
<p>NDC 66869-104-90
</p>
<p><span class="Bold">Livalo</span><span class="Sup">Â®</span><br>(pitavastatin) tablets
</p>
<p>1 mg*
</p>
<p><span class="Bold">Rx Only</span></p>
<p>LOGO-Kowa-LOGO
</p>
<div class="Figure">
<a name="f03"></a><img alt="Principal Display Panel - Bottle Label Livalo 1 mg
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=44dcbf97-99ec-427c-ba50-207e0069d6d2&amp;name=liv01-0003-03.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s73"></a><a name="section-17"></a><p></p>
<p class="First"><span class="Bold">Principal Display Panel - Bottle Label Livalo 2 mg</span></p>
<p>NDC 66869-204-90
</p>
<p>Livalo<span class="Sup">Â®</span><br>(pitavastatin) tablets
</p>
<p>2 mg*
</p>
<p><span class="Bold">Rx Only</span></p>
<p>LOGO-Kowa-LOGO
</p>
<div class="Figure">
<a name="f04"></a><img alt="Principal Display Panel - Bottle Label Livalo 2 mg
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=44dcbf97-99ec-427c-ba50-207e0069d6d2&amp;name=liv01-0003-04.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s74"></a><a name="section-18"></a><p></p>
<p class="First"><span class="Bold">Principal display Panel - Bottle Label Livalo 4 mg</span></p>
<p>NDC 66869-404-90
</p>
<p>Livalo<span class="Sup">Â®</span><br>(pitavastatin) tablets
</p>
<p>4 mg*
</p>
<p><span class="Bold">Rx Only</span></p>
<p>LOGO-Kowa-LOGO
</p>
<div class="Figure">
<a name="f05"></a><img alt="Principal display Panel - Bottle Label Livalo 4 mg
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=44dcbf97-99ec-427c-ba50-207e0069d6d2&amp;name=liv01-0003-05.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s75"></a><a name="section-19"></a><p></p>
<p class="First"><span class="Bold">Principal display Panel â€“ Carton 2 mg</span></p>
<p><span class="Bold">FREE SAMPLE</span>  NDC 66869-204-07
</p>
<p><span class="Bold">Livalo</span><span class="Sup">Â®</span></p>
<p>(pitavastatin) tablets
</p>
<p><span class="Bold">2 mg*</span></p>
<p><span class="Bold">Rx Only</span></p>
<p>Contains 7 Tablets
</p>
<p>LOGO-Kowa-LOGO
</p>
<p>Professional Sample â€“
</p>
<p>Not for Sale
</p>
<p>*Each tablet contains:<br>Active ingredient: pitavastatin calcium 2.09 mg equivalent to pitavastatin 2 mg.
</p>
<div class="Figure">
<a name="f06"></a><img alt="Principal display Panel â€“ Carton 2 mg
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=44dcbf97-99ec-427c-ba50-207e0069d6d2&amp;name=liv01-0003-06.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s76"></a><a name="section-20"></a><p></p>
<p class="First"><span class="Bold">Principal display Panel â€“ Carton 4 mg</span></p>
<p><span class="Bold">FREE SAMPLE</span>  NDC 66869-404-07
</p>
<p><span class="Bold">Livalo</span><span class="Sup">Â®</span><br>(pitavastatin) tablets
</p>
<p><span class="Bold">4 mg*</span></p>
<p><span class="Bold">Rx Only</span></p>
<p>Contains 7 Tablets
</p>
<p>LOGO-Kowa-LOGO
</p>
<p>Professional Sample â€“<br>Not for Sale
</p>
<p>*Each tablet contains:<br>Active ingredient: pitavastatin calcium 4.18 mg equivalent to pitavastatin 4 mg.
</p>
<div class="Figure">
<a name="f07"></a><img alt="Principal display Panel â€“ Carton 4 mg
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=44dcbf97-99ec-427c-ba50-207e0069d6d2&amp;name=liv01-0003-07.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>LIVALOÂ 		
					</strong><br><span class="contentTableReg">pitavastatin calcium tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:66869-104</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>pitavastatin calcium</strong> (pitavastatin) </td>
<td class="formItem">pitavastatin</td>
<td class="formItem">1.045Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>lactose monohydrate</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>hydroxypropyl cellulose, low substituted</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>hypromelloses</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>magnesium aluminometasilicate type i-b</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>titanium dioxide</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>triethyl citrate</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>silicon dioxide</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">white (White) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (Round) </td>
<td class="formLabel">Size</td>
<td class="formItem">6mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">1;KC
</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:66869-104-90</td>
<td class="formItem">90  in 1 BOTTLE, DISPENSING</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022363</td>
<td class="formItem">05/15/2010</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>LIVALOÂ 		
					</strong><br><span class="contentTableReg">pitavastatin calcium tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:66869-204</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>pitavastatin calcium</strong> (pitavastatin) </td>
<td class="formItem">pitavastatin</td>
<td class="formItem">2.09Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>lactose monohydrate</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>hydroxypropyl cellulose, low substituted</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>hypromelloses</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>magnesium aluminometasilicate type i-b</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>titanium dioxide</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>triethyl citrate</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>silicon dioxide</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">white (White) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (Round) </td>
<td class="formLabel">Size</td>
<td class="formItem">8mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">2;KC
</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:66869-204-90</td>
<td class="formItem">90  in 1 BOTTLE, DISPENSING</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:66869-204-07</td>
<td class="formItem">7  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022363</td>
<td class="formItem">05/15/2010</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>LIVALOÂ 		
					</strong><br><span class="contentTableReg">pitavastatin calcium tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:66869-404</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>pitavastatin calcium</strong> (pitavastatin) </td>
<td class="formItem">pitavastatin</td>
<td class="formItem">4.18Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>lactose monohydrate</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>hydroxypropyl cellulose, low substituted</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>hypromelloses</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>magnesium aluminometasilicate type i-b</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>titanium dioxide</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>triethyl citrate</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>silicon dioxide</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">white (White) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (Round) </td>
<td class="formLabel">Size</td>
<td class="formItem">10mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">4;KC
</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:66869-404-90</td>
<td class="formItem">90  in 1 BOTTLE, DISPENSING</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:66869-404-07</td>
<td class="formItem">7  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022363</td>
<td class="formItem">05/15/2010</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Kowa Pharmaceuticals America, Inc. 
							(119459589)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Kowa Company Limited</td>
<td class="formItem"></td>
<td class="formItem">717190628</td>
<td class="formItem">MANUFACTURE(66869-104), ANALYSIS(66869-104, 66869-204, 66869-404)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Nissan Chemical Industries, Ltd.</td>
<td class="formItem"></td>
<td class="formItem">706276847</td>
<td class="formItem">API MANUFACTURE(66869-104, 66869-204, 66869-404)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Patheon Pharmaceuticals Inc. </td>
<td class="formItem"></td>
<td class="formItem">005286822</td>
<td class="formItem">MANUFACTURE(66869-104), ANALYSIS(66869-104, 66869-204, 66869-404)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 10/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>b5e8d6e7-8ec4-4f72-9a54-ee4d69858eee</div>
<div>Set id: 44dcbf97-99ec-427c-ba50-207e0069d6d2</div>
<div>Version: 3</div>
<div>Effective Time: 20131022</div>
</div>
</div>Â <div class="DistributorName">Kowa Pharmaceuticals America, Inc. </div></p>
</body></html>
